Current Headlines

  1. Amarantus Receives Orphan Drug Designation For Eltoprazine
    2/11/2016

    Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that it has received orphan drug designation from the US FDA for Eltoprazine in the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID).

  2. Shire Marks 30th Anniversary With New Rare Diseases Program
    2/9/2016

    Three-Year Initiative Supports Next Generation of Medical Geneticists and  Enables Children to Take Part in Life-Changing Camp Experiences.

  3. CTI BioPharma Provides Update On Clinical Hold Of Pacritinib
    2/9/2016

    CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today provided an update regarding the clinical studies being conducted under the Company's Investigational New Drug ("IND") application for pacritinib. Following the issuance of the Company's February 8, 2016, press release describing the partial clinical hold issued by the U.S. Food and Drug Administration (FDA) regarding those clinical studies, the Company received an oral communication from the FDA followed by a letter notifying the Company that the Company's IND for pacritinib has been placed on full clinical hold.

  4. Air Liquide Announces the Acquisition PDP Couriers
    2/9/2016

    CRYO International, an Air Liquide group subsidiary specializing in temperature-controlled1 logistics solutions, has just acquired PDP Couriers, a major player in the customized transport of high value- added products for the pharmaceutical and biotechnology industries.

  5. Tobira Therapeutics Completes Patient Recruitment For ORION Phase 2a Study
    2/9/2016

    Tobira Therapeutics, Inc. (NASDAQ: TBRA), a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis (NASH) and other serious immuno-inflammatory and fibrotic diseases, announced that it has completed recruitment for the Phase 2a ORION study.

  6. PDS Biotechnology Signs Agreement With National Cancer Institute
    2/9/2016

    PDS Biotechnology (PDS), a clinical-stage biopharmaceutical company focused on developing a pipeline of simpler, safer and more effective cancer immunotherapies based on its novel Versamune® platform, today announced that the Company has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), an Institute of the U.S. National Institutes of Health. 

  7. Sartorius Stedim Offers New Crossflow Filtration System For Process Development
    2/8/2016

    Sartorius Stedim Biotech (SSB), an international leading supplier for the biopharmaceutical industry, announces the launch of SARTOFLOW Smart, the smart and easy benchtop crossflow system for optimized ultra- and diafiltration applications.

  8. Sangamo Announces FDA Clearance Of Investigational New Drug Application
    2/8/2016

    Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for SB-318, a single treatment strategy intended to provide a life-long therapy for Mucopolysaccharidosis Type I (MPS I).

  9. Marken The Preferred Partner To Fight Zika Virus
    2/8/2016

    Marken announced recently they are working with key pharma partners in the race to find a vaccine and treatment for the Zika virus, declared as a public health emergency by the World Health Organization (WHO) earlier this week.

  10. Ratan Tata Invests In Invictus Oncology
    2/8/2016

    Invictus Oncology Private Limited, an innovation-driven oncology company developing next generation cancer therapeutics that are more effective and less toxic, today announced that chairman emeritus of Tata Sons Limited, Mr Ratan N. Tata, has invested in the company as part of the first close of Invictus's Series A financing round, joining existing investors Navam Capital and Aarin Capital.